[go: up one dir, main page]

EA199800531A1 - Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона - Google Patents

Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона

Info

Publication number
EA199800531A1
EA199800531A1 EA199800531A EA199800531A EA199800531A1 EA 199800531 A1 EA199800531 A1 EA 199800531A1 EA 199800531 A EA199800531 A EA 199800531A EA 199800531 A EA199800531 A EA 199800531A EA 199800531 A1 EA199800531 A1 EA 199800531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acid
hydroxyrisperidone
pharmaceutically acceptable
active ingredient
acceptable carrier
Prior art date
Application number
EA199800531A
Other languages
English (en)
Other versions
EA000536B1 (ru
Inventor
Марк Карел Йозеф Франсуа
Роже Каролус Аугуста Эмбрехтс
Херман Карел Боргхейс
Йохан Монбалиу
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Publication of EA199800531A1 publication Critical patent/EA199800531A1/ru
Publication of EA000536B1 publication Critical patent/EA000536B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, подходящей в качестве препарата замедленного всасывания для внутримышечного или подкожного введения, содержащей: 1) в качестве активного ингредиента терапевтически эффективное количество сложного эфира жирной кислоты 9-гидроксирисперидона или его соли, или стереоизомера или стериоизомерной смеси; и 2) фармацевтически приемлемый носитель; где фармацевтически приемлемым носителем является вода и в ней суспендирован активный ингредиент; и к способу получения такой композиции. Кроме того, изобретение относится к фармацевтической композиции, применяемой в качестве лекарственного средства для лечения шизофрении, психозов нешизофренического происхождения, поведенческих расстройств, связанных с нейродегенеративными нарушениями, например со слабоумием, поведенческих нарушений, связанных с задержкой психического развития и аутизмом, биполярным маниакальным синдромом, депрессией и тревогой.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800531A 1996-05-20 1997-05-12 Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона EA000536B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
EA199800531A1 true EA199800531A1 (ru) 1998-12-24
EA000536B1 EA000536B1 (ru) 1999-10-28

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800531A EA000536B1 (ru) 1996-05-20 1997-05-12 Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона

Country Status (37)

Country Link
US (1) US6077843A (ru)
EP (1) EP0904081B1 (ru)
JP (1) JP3274687B2 (ru)
KR (1) KR100358373B1 (ru)
CN (1) CN1093762C (ru)
AR (1) AR007194A1 (ru)
AT (1) ATE208619T1 (ru)
AU (1) AU715572B2 (ru)
BG (1) BG62684B1 (ru)
BR (1) BR9706824B8 (ru)
CA (1) CA2236691C (ru)
CY (2) CY2270B1 (ru)
CZ (1) CZ291284B6 (ru)
DE (2) DE69708284T2 (ru)
DK (1) DK0904081T3 (ru)
EA (1) EA000536B1 (ru)
EE (1) EE03594B1 (ru)
ES (1) ES2167745T3 (ru)
FR (1) FR11C0035I2 (ru)
HR (1) HRP970276B1 (ru)
HU (2) HU224025B1 (ru)
ID (1) ID16927A (ru)
IL (1) IL124551A (ru)
LU (1) LU91842I2 (ru)
MX (1) MX9804816A (ru)
MY (1) MY126302A (ru)
NO (2) NO315931B1 (ru)
NZ (1) NZ330369A (ru)
PL (1) PL188309B1 (ru)
PT (1) PT904081E (ru)
SI (1) SI0904081T1 (ru)
SK (1) SK284013B6 (ru)
TR (1) TR199800923T2 (ru)
TW (1) TW487572B (ru)
UA (1) UA61898C2 (ru)
WO (1) WO1997044039A1 (ru)
ZA (1) ZA974331B (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (ru) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Водные суспензии субмикронной формы эфиров 9-гидроксирисперидона жирных кислот
JP2002504505A (ja) * 1998-02-25 2002-02-12 アボット・ラボラトリーズ ブトルファノール持続放出性製剤
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
EA200401009A1 (ru) 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ES2310410T3 (es) * 2000-08-14 2009-01-01 Teva Pharmaceutical Industries Ltd. Preparacion de risperidona.
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
CN101641353B (zh) * 2007-04-19 2012-05-23 长春健欣生物医药科技开发有限公司 用于治疗精神疾病的新颖化合物及其制备方法和用途
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
LT2234617T (lt) 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CN104248623B (zh) 2008-09-04 2020-04-03 安米林药品有限责任公司 使用非水性载体的持续释放制剂
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CA2742393A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (en) * 2011-05-31 2016-05-25 Ramamohan Rao, Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HUE049485T2 (hu) 2015-04-07 2020-09-28 Janssen Pharmaceuticals Inc Adagolási rend hosszan ható, injektálható paliperidon-észterek beadásának elmaradása esetén
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
TWI814219B (zh) 2016-05-16 2023-09-01 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
HRP20240074T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
TW202222317A (zh) 2020-11-30 2022-06-16 比利時商健生藥品公司 與延釋帕利哌酮可注射配製物相關之投藥方案（一）
LT4025187T (lt) 2020-11-30 2024-02-12 Janssen Pharmaceutica Nv Dozavimo režimai, susiję su prailginto atpalaidavimo injekcinėmis paliperidono vaisto formomis
EP4005555B1 (en) 2020-11-30 2024-05-15 Janssen Pharmaceutica NV Methods for ensuring resuspension of paliperidone palmitate formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
AU2022329095A1 (en) 2021-08-20 2024-04-04 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE212830T1 (de) * 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
JP3057763B2 (ja) * 1995-06-06 2000-07-04 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病薬としてのベンゾイソオキサゾール及びインダゾール誘導体
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
AU2955997A (en) 1997-12-09
ZA974331B (en) 1998-11-19
UA61898C2 (en) 2003-12-15
HRP970276B1 (en) 2002-04-30
CN1093762C (zh) 2002-11-06
EP0904081B1 (en) 2001-11-14
KR19990067603A (ko) 1999-08-25
FR11C0035I1 (ru) 2011-07-10
HU224025B1 (hu) 2005-05-30
DK0904081T3 (da) 2002-02-25
NO315931B1 (no) 2003-11-17
ID16927A (id) 1997-11-20
MY126302A (en) 2006-09-29
LU91842I2 (fr) 2011-09-20
TR199800923T2 (xx) 1999-09-21
BG102443A (en) 1999-06-30
JP2000513718A (ja) 2000-10-17
HUS1100013I1 (hu) 2017-03-28
DE69708284T2 (de) 2002-07-25
CN1206347A (zh) 1999-01-27
DE69708284D1 (de) 2001-12-20
IL124551A (en) 2001-08-26
KR100358373B1 (ko) 2003-02-11
SK284013B6 (sk) 2004-08-03
SI0904081T1 (en) 2002-04-30
TW487572B (en) 2002-05-21
US6077843A (en) 2000-06-20
NZ330369A (en) 2000-04-28
CZ140198A3 (cs) 1999-04-14
BG62684B1 (bg) 2000-05-31
CA2236691C (en) 2007-01-02
MX9804816A (es) 1998-10-31
PL327995A1 (en) 1999-01-04
CY2270B1 (en) 2003-07-04
HK1017852A1 (en) 1999-12-03
EA000536B1 (ru) 1999-10-28
CA2236691A1 (en) 1997-11-27
HRP970276A2 (en) 1998-04-30
ES2167745T3 (es) 2002-05-16
HUP9901319A2 (hu) 1999-08-30
PT904081E (pt) 2002-04-29
IL124551A0 (en) 1998-12-06
SK62098A3 (en) 2000-04-10
EE9800136A (et) 1998-10-15
DE122011100027I1 (de) 2011-11-17
PL188309B1 (pl) 2005-01-31
NO981984L (no) 1998-11-19
EP0904081A1 (en) 1999-03-31
NO2011015I2 (no) 2013-03-11
AU715572B2 (en) 2000-02-03
BR9706824B8 (pt) 2015-02-18
CY2011011I1 (el) 2016-12-14
CY2011011I2 (el) 2016-12-14
EE03594B1 (et) 2002-02-15
JP3274687B2 (ja) 2002-04-15
WO1997044039A1 (en) 1997-11-27
FR11C0035I2 (fr) 2013-08-16
AR007194A1 (es) 1999-10-13
CZ291284B6 (cs) 2003-01-15
HUP9901319A3 (en) 1999-11-29
BR9706824A (pt) 1999-03-23
ATE208619T1 (de) 2001-11-15
NO981984D0 (no) 1998-04-30
NO2011015I1 (no) 2011-09-19

Similar Documents

Publication Publication Date Title
EA199800531A1 (ru) Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона
EA200000541A1 (ru) Водные суспензии субмикронных 9-гидроксирисперидоновых сложных эфиров жирных кислот
FI970634A0 (fi) Syklosporiinien uudet, suun kautta annettavat, koostumukseltaan yksinkertaiset valmistemuodot, joista biosaatavuus on hyvä, sekä menetelmä niiden valmistamiseksi
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
LV12766A (lv) Composition of l-dopa esters
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
IT1256345B (it) Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
ATE178044T1 (de) Inhibitoren des arginin-ketoamid-enzyms
PT716600E (pt) Composicoes para administracao topica contendo derivados do acido 3-benzoilfenilacetico para o tratamento de doencas inflamatorias oftalmicas
UA41446C2 (ru) Применение фумагилола и его производных для получения лекарств, предназначенных для борьбы с кишечными инфекциями, и фармацевтическая композиция на их основе
IL120317A0 (en) Otic antibacterial compositions
MX9102209A (es) Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso.
FR2724384B1 (fr) Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
FR2649110B1 (fr) Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1987004926A3 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
AR010237A1 (es) Compuestos acidos carboxilicos azaheterociclicos n-sustituidos, un metodo para su preparacion, composicion farmaceutica y uso de los mismos para lapreparacion de composiciones farmaceuticas
KR930702965A (ko) 생체이용성이 개선된 프로부콜 함유 제약 조성물
KR910009259A (ko) 천식 또는 특정 피부 질환의 치료를 위한 피리미돈 유도체 및 동족체
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR008245A1 (es) Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
AU7338587A (en) Pharmaceutical compositions of furosemide, piretanide or lemidosul in a fatty acid alkanolamide base

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU